Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Development of Smart Food /Nutraceutical Solutions Dedicated to Cardiometabolic Disorders in Ageing (NutriAge)

11 september 2026 uppdaterad av: Flavia Prodam, Azienda Ospedaliero Universitaria Maggiore della Carita

NUTRI.AGE: DEVELOPMENT OF SMART FOOD/NUTRACEUTICAL SOLUTIONS DEDICATED TO CARDIOMETABOLIC DISORDERS IN AGEING

Describe the anthropometric measurements and informations relating to body composition, blood chemistry tests, blood glucose monitoring, and dietary habits of the volunteers participating in the study before and after taking probiotics.

Studieöversikt

Status

Rekrytering

Betingelser

Intervention / Behandling

Detaljerad beskrivning

The clinical research is aimed at exploring the in vivo functionality in humans of ingredients produced and formulated at a pre-competitive pilot level, namely the ability to reduce blood pressure or modify the RAAS (renin-angiotensin-aldosterone system) through the presence of substrates with ACE-inhibitory activity, and/or improve metabolic status through the administration of probiotic strains whose products have a known metabolic effect in in vitro, in vivo animal, or human models (in other subject categories). The use of "enhanced bioactive compounds" (ACE inhibitors, pre-, pro-, and post-biotics) together with selected probiotics in newly formulated food supplements may be strategic in supporting specific diets and pharmacological treatments in older adults with cardiometabolic disorders (CVD). The result of these technological convergences will culminate with the in vivo trial of some nutraceutical-food systems useful for the well-being of the elderly suffering from cardiometabolic pathologies (CVDs).

Studietyp

Interventionell

Inskrivning (Beräknad)

15

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

      • Novara, Italien, 28100
        • Rekrytering
        • SCDU Endocrinology. AOU Ospedale Maggiore della Carità
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Äldre vuxen

Tar emot friska volontärer

Ja

Beskrivning

Inclusion Criteria:

  • Patients of either gender, over 65 years of age, able to understand the protocol procedures.
  • Known cardiovascular disease
  • Prediabetes or type 2 diabetes mellitus with HbA1c < 7.0% on diet alone or metformin.

Exclusion Criteria:

  • Age under 65
  • Previous diagnosis of type 2 diabetes mellitus already undergoing drug therapy (except metformin)
  • Contraindications such as allergy to product components
  • Obesity secondary to diseases: genetic (Prader-Willi syndrome, Down syndrome); metabolic and endocrine (Cushing's syndrome, hypothyroidism)
  • Endocrine or liver disease or clinical evidence of chronic disease or gastrointestinal disorders or malabsorption disorders
  • History of adrenal adenoma or secondary arterial hypertension due to renal/adrenal causes
  • Arterial hypertension treated with an ACE inhibitor or ARB
  • Previous bariatric surgery

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Stödjande vård
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Placebo
Participants will receive a placebo for 60 days to allow comparison of the results with those observed in the intervention arm. Participants will take one placebo capsule once daily in the morning, on an empty stomach.
Participants will receive a probiotic for 60 days to allow comparison of the results with those observed in the placebo arm. Participants will take one probiotic capsule once daily in the morning, on an empty stomach.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Blood glucose assessment with OGTT test and FGM
Tidsram: 4 months
Blood glucose and insulin tests at 0', 30', 60', 90', 120' minutes every 30 minutes Blood glucose monitoring at home
4 months
Pressure assessment
Tidsram: 4 months
Blood pressure is assessed during the visit at time 0 and after 60 days Filling out a blood pressure diary at home
4 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Anthropometric measurements
Tidsram: evaluation of weight and body composition through study completion, an average of 4 months
Weight is assessed in Kg with the use of the bioimpedance balance.
evaluation of weight and body composition through study completion, an average of 4 months
Anthropometric measurements
Tidsram: evaluation of weight and body composition through study completion, an average of 4 months
the height is measured in cm through a wall altimeter
evaluation of weight and body composition through study completion, an average of 4 months
Anthropometric measurements
Tidsram: evaluation of weight and body composition through study completion, an average of 4 months
the BMI (body mass index) is calculated by making the ratio of the weight to the square of the height. normal weight is defined as 18.5-24.9 kg/m², overweight as 25.0-29.9 kg/m², and obesity as ≥30.0 kg/m
evaluation of weight and body composition through study completion, an average of 4 months
Anthropometric measurements
Tidsram: evaluation of weight and body composition through study completion, an average of 4 months
Waist, hip, arm, and calf circumferences are measured using an inelastic measuring tape. Waist circumference is also assessed as an indicator of abdominal obesity and increased cardiometabolic risk, using the following reference cut-off values for European populations: ≥94 cm in men and ≥80 cm in women.
evaluation of weight and body composition through study completion, an average of 4 months
Adherence level to the Western diet with European Prospective Investigation into Cancer and Nutrition (EPIC) questionnaires
Tidsram: evaluation of weight and body composition through study completion, an average of 4 months
Assessed with the use of questionnaire. EPIC is used for the bromatology evaluation of the diet, so there aren't scales but only indication about the macro and micronutrient composition. This is a qualitative questionnaires and not quantitative.
evaluation of weight and body composition through study completion, an average of 4 months
Adherence level to the Western diet with 24h recall questionnaires
Tidsram: evaluation of weight and body composition through study completion, an average of 4 months
Assessed with the use of questionnaires. 24h recall questionnaire is used for the bromatology evaluation of the diet, so there aren't scales but only indication about the macro and micronutrient composition. This is a qualitative questionnaires and not quantitative.
evaluation of weight and body composition through study completion, an average of 4 months
Advanced glycation end products quantification
Tidsram: evaluation of weight and body composition through study completion, an average of 4 months
AGE levels will be measured using skin fluorescence, using the "AGE reader mu" device (range from 1.3 to 5 level of AGEs respect to the patient's age)
evaluation of weight and body composition through study completion, an average of 4 months
Endogenous and exogenous AGEs plasma quantification
Tidsram: evaluation of weight and body composition through study completion, an average of 4 months
AGEs will also be assessed at the plasma level in free form (ELISA, fluorescence assay) or bound to hemoglobin (HbA1c clinical practice test), both measured in pg/mL
evaluation of weight and body composition through study completion, an average of 4 months
Soluble RAGEs plasma quantification
Tidsram: evaluation of weight and body composition through study completion, an average of 4 months
RAGEs will also be assessed at the plasma level in solule form (ELISA) measured in pg/mL
evaluation of weight and body composition through study completion, an average of 4 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Flavia Prodam, MD PhD, AOU Maggiore della Carita

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

  • [1] Vadim N. GladyshevAging: progressive decline in fitness due to the rising deleteriome adjusted by genetic, environmental, and stochastic processes,06 April 2016 https://doi.org/10.1111/acel.12480. [2] Guo, J., Huang, X., Dou, L. et al. Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Sig Transduct Target Ther 7, 391 (2022). https://doi.org/10.1038/s41392-022-01251-0. [3] http://dati-anziani.istat.it/Index.aspx [4] https://www.salute.gov.it/portale/documentazione/p6_2_2_1.jsp?id=3074 [5] Ilse Bloom, Mark Edwards, Karen A. Jameson, Holly E. Syddall, Elaine Dennison, Catharine R. Gale, Janis Baird, Cyrus Cooper, Avan Aihie Sayer, Sian Robinson, Influences on diet quality in older age: the importance of social factors, Age and Ageing, Volume 46, Issue 2, March 2017, Pages 277-283, https://doi.org/10.1093/ageing/afw180 [6] https://doi.org/10.1093/ageing/afw180Ragonnaud, E., Biragyn, A. Gut microbiota as the key controllers of "healthy" aging of elderly people. Immun Ageing 18, 2 (2021). https://doi.org/10.1186/s12979-020-00213-w [7] Nuria Salazar, Lorena Valdés-Varela, Sonia González, Miguel Gueimonde & Clara G. de los Reyes-Gavilán (2017) Nutrition and the gut microbiome in the elderly, Gut Microbes, 8:2, 82- 97, DOI: 10.1080/19490976.2016.1256525 [8] Białecka-Dębek, A.; Granda, D.; Szmidt, M.K.; Zielińska, D. Gut Microbiota, Probiotic Interventions, and Cognitive Function in the Elderly: A Review of Current Knowledge. Nutrients 2021, 13, 2514. https://doi.org/10.3390/nu13082514 [9] Hutchinson, A.N.; Bergh, C.; Kruger, K.; Sűsserová, M.; Allen, J.; Améen, S.; Tingö, L. The Effect of Probiotics on Health Outcomes in the Elderly: A Systematic Review of Randomized, Placebo-Controlled Studies. Microorganisms 2021, 9, 1344. https://doi.org/10.3390/microorganisms9061344 [10] ALE, Elisa C.; BINETTI, Ana G. Role of probiotics, prebiotics, and synbiotics in the elderly: insights into their applications. Frontiers in Microbiology, 2021, 12: 631254. [11] Wu, H.; Chiou, J. Potential Benefits of Probiotics and Prebiotics for Coronary Heart Disease and Stroke. Nutrients 2021, 13, 2878. https://doi.org/10.3390/nu13082878 [12] Kiersnowska K, Jakubczyk A. Bioactive Peptides Obtained from Legume Seeds as New Compounds in Metabolic Syndrome Prevention and Diet Therapy. Foods. 2022 Oct 21;11(20):3300. doi: 10.3390/foods11203300. PMID: 37431048; PMCID: PMC9602117. [13] Alexander R, Khaja A, Debiec N, Fazioli A, Torrance M, Razzaque MS. Health-promoting benefits of lentils: Anti-inflammatory and anti-microbial effects. Curr Res Physiol. 2024 Mar 5;7:100124. doi: 10.1016/j.crphys.2024.100124. PMID: 38501131; PMCID: PMC10945126. [14] Rezvankhah A, Yarmand MS, Ghanbarzadeh B, Mirzaee H. Development of lentil peptides with potent antioxidant, antihypertensive, and antidiabetic activities along with umami taste. Food Sci Nutr. 2023 Feb 27;11(6):2974-2989. doi: 10.1002/fsn3.3279. PMID: 37324857; PMCID: PMC10261806. [15] Nicola Faccilongo, Giustina Pellegrini, Piermichele La Sala, Economia circolare e scarti nelle filiere agroalimentari: prima indagine esplorativa sullo stato dell'arte, in

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

24 juni 2025

Primärt slutförande (Faktisk)

30 september 2025

Avslutad studie (Beräknad)

30 november 2026

Studieregistreringsdatum

Först inskickad

7 september 2026

Först inskickad som uppfyllde QC-kriterierna

11 september 2026

Första postat (Faktisk)

14 september 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

14 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

11 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera